A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Ryan Mattison, Alcee Jumonville, Patrick James Flynn, Alvaro Moreno-Aspitia, Charles Erlichman, Betsy Laplant, Mark B. Juckett

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences